Industry News

• Hi-Tech Pharmacal reports sales of $40.4 million for the quarter ended July 31. 2010  Hi-Tech Pharmacal reported net income of $8,675,000 for the three months ended July 31, 2010 versus net income of $8,674,000 for the same period in the prior year, and net sales for the 2010 period were $40,400,000, versus net sales of $43,477,000, for the three months ended July 31, 2009. .
  Hi-Tech Pharmacal Co., Inc. September 08, 2010  
• Helicos BioSciences files patent infringement lawsuit against Pacific Biosciences  Helicos BioSciences announced that it has filed a lawsuit against Pacific Biosciences in California for patent infringement. The lawsuit, filed in the U.S. District Court for the District of Delaware, accuses PacBio of infringing four patents and seeks injunctive relief and monetary damages.
  Helicos BioSciences Corporation September 08, 2010  
• Emergent announces early termination of HSR waiting peiod for Trubion acquisition  Emergent announced the U.S. Department of Justice and FTC granted early termination of the waiting period with respect to their acquisition of Trubion Pharmaceuticals announced August 12, 2010. The closing of the transaction remains subject to approval by Trubion's stockholders.
  Emergent BioSolutions Inc. September 08, 2010  
• Progenics initiates oral methylnaltrexone phase 3 trial in patients with chronic pain  Progenics Pharmaceuticals announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens.
  Progenics Pharmaceuticals, Inc. September 08, 2010  
• New patient safety alliance launches tools to fight pain medication misuse and abuse  The C.A.R.E.S. Alliance, a new patient safety organization, launched a range of online tools designed to help solve the growing problem of misuse and abuse of opioids by identifying the risks associated with these powerful pain medications.
  Covidien September 08, 2010  
• Emergent announces phase I trial for monoclonal antibody to treat inhalational anthrax   Emergent BioSolutions announced that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced. Emergent’s fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
  Emergent BioSolutions Inc. September 08, 2010  
• Abbott completes acquisition of India's Piramal Healthcare Solutions business  Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian market and further accelerating the company's growth in emerging markets. Abbott expects its pharmaceutical sales in India to exceed $2.5 billion by 2020.
  Abbott September 08, 2010  
• Targeted drug for melanoma shows promise in early clinical testing  The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers announced last month.
  National Cancer Institute September 07, 2010  
• Bristol-Myers Squibb announces dividend  The Board of Directors of Bristol-Myers Squibb declared a quarterly dividend of 32 cents ($0.32) per share on the $0.10 par value Common Stock of the corporation. The quarterly dividend will be payable on November 1, 2010 to stockholders of record at the close of business on October 1, 2010.
  Bristol-Myers Squibb Company September 07, 2010  
• PPD Establishes network of sites for conducting phase I trials in patients  PPD announced it has established preferred provider relationships with a network of sites across North America for conducting Phase I trials in patients to meet growing client demand for these services, including Commonwealth Biomedical Research, CNS Network and Lovelace Scientific Resources.
  PPD, Inc. September 07, 2010  

(previous 10 articles)    (next 10 articles)